Shots:
- Union to receive $20M up front and is eligible to receive ~$247M in milestone along with royalties on sales of orismilast in China & holds the global rights for the product outside of China
- Innovent gets an exclusive license to research, develop and commercialize orismilast (PDE4 Inhibitor) in China, including participating and recruiting Chinese patients for global studies
- In P-IIa clinical studies, orismilast demonstrated a superior profile with improved efficacy and tolerability. The therapy has provided POC data orally in psoriasis or AD & is well suited to address the unmet needs of the patient populations
Click here to read full press release/ article | Ref: PR Newswire | Image: Innovent
The post Innovent Signs a License Agreement with Union to Develop & Commercialize Orismilast for Inflammatory Dermatology Conditions in China first appeared on PharmaShots.
